FSB Premier Wealth Management Inc. Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

FSB Premier Wealth Management Inc. boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 132.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,128 shares of the medical research company’s stock after purchasing an additional 1,214 shares during the period. FSB Premier Wealth Management Inc.’s holdings in IQVIA were worth $450,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of IQV. Versant Capital Management Inc boosted its holdings in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new stake in shares of IQVIA during the second quarter valued at $27,000. Rise Advisors LLC bought a new position in shares of IQVIA in the first quarter worth about $31,000. Riverview Trust Co purchased a new position in IQVIA in the 1st quarter worth about $32,000. Finally, International Assets Investment Management LLC bought a new stake in IQVIA during the 2nd quarter valued at about $32,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research reports. Jefferies Financial Group lowered shares of IQVIA from a “buy” rating to a “hold” rating and reduced their target price for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. The Goldman Sachs Group initiated coverage on IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective on the stock. Robert W. Baird upped their target price on IQVIA from $235.00 to $251.00 and gave the stock a “neutral” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. increased their price target on IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Finally, Royal Bank of Canada assumed coverage on shares of IQVIA in a research note on Wednesday. They issued an “outperform” rating and a $275.00 price objective for the company. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $266.25.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is owned by insiders.

IQVIA Stock Performance

Shares of IQV opened at $248.71 on Wednesday. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The stock has a fifty day moving average price of $232.82 and a 200-day moving average price of $234.41. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The firm has a market cap of $45.34 billion, a PE ratio of 33.98, a P/E/G ratio of 2.37 and a beta of 1.49.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same period last year, the business posted $2.22 earnings per share. The firm’s revenue was up 2.3% compared to the same quarter last year. Equities research analysts predict that IQVIA Holdings Inc. will post 10.24 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.